Dr Wolf Peter Kremer, MD | |
461 Cambridge St, Apt # 1, Allston, MA 02134-2023 | |
(504) 931-6961 | |
Not Available |
Full Name | Dr Wolf Peter Kremer |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 461 Cambridge St, Allston, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417025834 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 228789 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Wolf Peter Kremer, MD 461 Cambridge St, Apt # 1, Allston, MA 02134-2023 Ph: (504) 931-6961 | Dr Wolf Peter Kremer, MD 461 Cambridge St, Apt # 1, Allston, MA 02134-2023 Ph: (504) 931-6961 |
News Archive
Since 1999, stroke survivors have been advised to use aspirin, prescription antiplatelet agents, or prescription anticoagulants to help avoid another stroke. Many large surveys of the U.S. population have reported the use of aspirin for secondary prevention, but commonly combine people with stroke and coronary artery disease, and only rarely report the use of antithrombotic agents other than aspirin.
MILabs is pleased to announce that Sunnybrook Research Institute, the research arm of the Sunnybrook Health Sciences Centre, located in Toronto, Canada will install a MILabs VECTor+ system to expand their current preclinical molecular imaging capabilities.
Ormond Beach, FL – December 7, 2020 – CO2Meter, Inc. has partnered with a national pharmacy chain to keep their customers and employees safe from the potentially hazardous effects of CO2 exposure from the dry ice that is keeping the COVID-19 vaccines cold.
New research findings may shed new light on the potential cause of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
› Verified 1 days ago